The role played by bacterial infections in the onset and metastasis of cancer

Sajmina Khatun, Tejaswini Appidi, Aravind Kumar Rengan*

Department of Biomedical Engineering, IIT Hyderabad, Kandi, Sangareddy 502284, Telangana, India

1. Introduction

Cancer remains a prime cause of morbidity and mortality worldwide. It is a resultant of the extensive and uncontrollable proliferation of cells. These cells are heterogenous and constantly evolve evading immune responses, developing drug resistance and recurrence (Gallaher et al., 2019). An adequate understanding of the biological components provoking cancer progression can reduce the mortality rate. Extensive efforts of researchers concluded, the intrinsic risk factors (such as an error in DNA replication/spontaneous mutations) cause only 10–30% of cancer. The extrinsic risk factors (endogenous risk factors: biological ageing, genetic susceptibility, hormones, etc., and exogenous risk factors: chemical carcinogens, tumour-causing micro-organisms, unhealthy lifestyles, etc.) are the significant drivers of cancer progression (Wu et al., 2016). In 2018, about 18.1 million new cancer cases were recorded worldwide (Bray et al., 2018). In 2020 19.3 million new cancer cases and 10 million deaths have been reported, indicating the rampant cancer progression worldwide. The cancer cases are expected to increase further and reach 28.4 million by 2040 (World Health Organisation 2018; Sung et al., 2021). A better understanding of cancer-causing factors, early detection, and improvised therapy is crucial and highly required to address cancer fatality.

Various environmental factors can cause changes in the host-genetic relationship leading to cancer development. Micro-organisms like bacteria, viruses, fungi colonizing the gastrointestinal tract, mouth, skin and vagina could be vital and potential environmental factors. Infectious agents contribute to 16.1% of malignancy worldwide (Takeshima and Ushijima, 2019; Dekaboruah et al., 2020; De Martel et al., 2012). Micro-organisms can colonize inside and outside the body without harmful effects as commensals or mutuals (living with beneficial co-relation with host cells). However, an imbalance between organisms, i.e. dysbiosis, alters the normal physiological homeoestasis in host cells. This unhealthy relationship between host and microbes leads to various diseases like obesity (Turnbaugh et al., 2006), malnutrition (Blanton et al., 2016), diabetes (Al-Rawi and Al-Marzooq, 2017), chronic inflammatory diseases such as inflammatory bowel disease (IBD) (Manzanier et al., 2008), and cancer (Polk and Peek, 2010). An average human (aged 20–30 years with a bodyweight of 70 kg and a height of 170 cm) contains about 3.8 × 10^{13} bacterial cells. The colon alone contains 10^{11} bacterial cells, and the stomach, duodenum, jejunum (upper small intestine) contains 10^{2–3} × 10^{4} bacterial cells (Sender et al., 2016). The interactions between the microbes and the host cells are
diverse, making it hard to determine and define the exact role played by microbiota in cancer progression. The microbiota-mediated infection has been reported as a potent cancer-inducing factor that triggers cancer progression by attacking the host cell DNA, modulating the immune system, inducing inflammation, hormone secretion, lymphoproliferation, and promoting epithelial-mesenchymal transition (EMT) (Geng et al., 2020; Paciello et al., 2013; Grebowska et al., 2008; Leclercq et al., 2016; Jin et al., 2019; Rosean et al., 2019; Li et al., 2019). The microbes translocate, causes genotoxicity and affect the metabolism altering the host cell’s environment. The symbiotic relations between bacteria and host cells, when disrupted, lead to translocation of bacteria into host cells, triggers inflammation leading to the development of tumours. Bacterial genotoxins like colibactin, CDTs (cytolethal distending toxin) are known to break the host cells’ DNA (Li et al., 2019; Shine et al., 2018; Zhou et al., 2020). Microbiota is also known for altering the gut’s bile acid homeostasis, catalysing deconjugation and dihydroxylation (Wang et al., 2019; Li et al., 2020).

Microbiota and cancer have a bi-modal relationship, as represented in Fig. 1. Though microbiota plays a critical role in triggering and progression of malignancy, it is also an emerging cancer therapy approach (Zhang et al., 2018; Yu et al., 2012; Park et al., 2017; Park et al., 2013a). Conventional cancer therapies, like chemotherapy, surgery, radiation, etc., lack target specificity and adverse side effects. The traditional cancer drugs cannot penetrate the tumour tissues deeply, and some of the tumour tissues develop drug resistance as well (Navya et al., 2019; Maeda and Khatami, 2018). The unique internal pathophysiology of solid tumours and the limitations of conventional treatments indicate the immediate need for new therapeutic modalities. Several alternative treatments like photodynamic therapy, gene therapy, insulin potentiating therapy, human alpha-lactalbumin made lethal to tumour cells (HAMLET), telomerase therapy, hyperthermia, dichloroacetate, non-invasive radiofrequency cancer treatment, etc. have been explored for enhanced therapeutic efficacy (Sedighi et al., 2019). Bacteria have an advantage over all the approaches mentioned above: they can perforate into the tumour, colonize in its hypoxic core, and the body does not show any immune resistance, making it a more practical therapeutic approach (Zhang et al., 2018; Yu et al., 2012; Park et al., 2017). Application of non-pathogenic bacteria for anticancer drug delivery leads to regression of tumour growth (Zhang et al., 2018; Jiang et al., 2010; Xiong et al., 2013; Sawant et al., 2020).

This review discusses the inter-relation between bacteria and cancer, cancer-causing virulence factors, and infections. We have also explored the various mechanisms to understand the role played by bacteria in the development and progression of cancer. Finally, the application of bacteria for cancer therapy is also discussed.

2. Understanding the mechanism of cancer progression

It is arduous to identify the particular bacterial species that causes cancer, as more than a million bacterial species are present in the human body. For example, the colon alone contains more than 100 trillion bacterial species, and the oral cavity contains over 500 bacterial species. Furthermore, a bacterial species found to be responsible for cancer progression follows different mechanisms at different sites. Example: *Fusobacterium* can cause both oral and colon carcinoma (Dekaboruah et al., 2020; Rubinstein et al., 2013; Harrandah et al., 2021). The mechanisms by which bacteria promotes malignancy and metastasis are discussed in detail in this section.
2.1. Chronic inflammation

The inflammatory reaction protects the host cells by fighting the foreign organisms, but inflammation/chronic inflammation persistence leads to cancer development. Several studies showed that chronic inflammation acts as a plethoric driving force in cancer development, intensifying malignant transformation, tumour growth, invasion, and metastasis. About 25% of human cancer is associated with chronic inflammation. Inflammation shows greater replicative potential and self-determination of growth factors. Furthermore, growth inhibition is also absent in inflammation conditions with a legit escape from apoptosis. All these factors lead to tumour extravasation and have great potential to enhance angiogenesis (Afrasiabi et al., 2015; Cruz and Balkwill, 2015; Gruffaz et al., 2017). The mechanism of chronic inflammation leading to cancer development and progression is not specific to bacteria. Other micro-organisms like viruses (Liu et al., 2015) and fungi (Ramirez-Garcia et al., 2013) can also promote an inflammatory pathway leading to cancer metastasis.

Inflammation is a natural immune response to protect host cells. Phagocytes recruited to the infection site secrete several pro-inflammatory cytokines like TNF-α (tumour necrosis factor-alpha), IL-23, IL-1, attracting other immune cells, enhancing the inflammatory response. These inflammatory responses activate STAT3 and NF-κβ signalling pathways, triggering uncontrolled cell proliferation. The recruited immune cells increase reactive oxygen species (ROS) and nitrogen oxide species (NOS) by activating enzyme-like NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, superoxide dismutase (SOD), nitric oxide synthase (NOS), etc. These free radicals further kill pathogens (Messex et al., 2020; Duque and Descoteaux, 2014b). However, these free radicals and derived metabolic products like HNO2, N2O3, peroxynitrite also damage proteins, DNA, and cell membranes. The damaged DNA is propagated through uncontrolled cell division, escaping the cell cycle check-point and repair system, leading to point mutations, deletion, and translocation. Hence chronic inflammation is associated with DNA damage, mutation, and aberrant cell differentiation, provoking cancer development (Habib and Moinuddin, 2005; Teshima et al., 2018; Irrazabal et al., 2020).

Fig. 2 shows the schematic illustration of how bacterial dysbiosis causes chronic inflammation and cancer. For example, *H. pylori* infection causes an influx of phagocytic cells (macrophage and neutrophils) in an attempt to kill the pathogens. These phagocytic cells release ROS/RNS (reactive oxygen species/reactive nitrogen species) to clear the infection. However, the persistence of these free radicals damages the epithelial cells, leading to cancer development (den Hartog et al., 2016; Ding et al., 2007). *H. pylori* induces inflammation via several mechanisms, of which cagPAI mediated NF-κβ induction was discussed earlier in detail (2.1. Gastric cancer) (Chen et al., 2016; Krisch et al., 2016; Epiya-motifs, 2019; Stein et al., 2002). In addition, *H. pylori* also causes inflammation in gastric epithelial cells via their surface adhesion proteins like OipA (outer inflammatory protein OipA) and BabA (blood group antigen binding adhesin). These proteins aid in the longer persistence of bacteria in host epithelial cells, induces the secretion of pro-inflammatory cytokines like IL-6, IL-11, causing severe inflammation and develops stomach cancer (Sugimoto et al., 2011). *F. nucleatum* also has surface...
adhesion proteins: FadA (fusobacterium adhesin A), Fap2 (fibroblast activation protein 2), and RadD (radiation gene D). Researchers have found that FadA modulates the tumour micro-environment by down-regulating the tight junction proteins: cadherin and its functional association with catenin, evoking chronic inflammation and cancer metastasis (Rubinstein et al., 2013; Kaplan et al., 2010).

2.2. Cross talk between bacterial infections and immune system

The crosstalk between bacteria and immune system results in multifold interactions causing homeostasis and pathogenesis. The commensal bacteria play an essential role in training and functionalizing major components of the host's innate and adaptive immune system. The innate immune system is composed of several pattern recognition receptors (PRRs). These PRRs have broad specificity towards antigens and can bind to many molecules with a common structural motif present in pathogens called pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) released by the damaged cells. There are several PRRs like toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD) and leucine-rich repeats (LRR)-containing receptors (NLR), retinoic acid-inducible gene 1 (RIG-1) -like receptors (RLR) and C-type lectin receptors (CLRs). Among all these PRRs, TLRs are the most crucial pattern recognition receptors to elicit antimicrobial and inflammatory responses.

In contrast, the adaptive immune system consists of several effector immune cells like B and T cells. It recognizes the antigen by multiple antigen receptors, distributed on B and T cells. The genetic and somatic recombination of these receptors on B and T cells generates multiple repertoires of receptors. These receptors enable the identification of clonal selection of antigen-specific receptors and develop immunological memory. These receptors enable the identification of a clonal selection of antigen-specific receptors and develop immunological memory. After TLRs become activated by PAMPs/DAMPs, an immune response is transmitted to macrophages/B cells/ T cells. The activated immune cells produce pro-inflammatory cytokines like tumour-necrosis factor alpha (TNF α), interleukin-1β (IL-1β) and IL-6, neutralizing antigens. Therefore innate and adaptive immune responses commingle to kill pathogens (Amarante-Mendes et al., 2018; Chi et al., 2020).

Many bacteria present in the host's gut environment maintain a symbiotic/mutualistic relationship with the host immune system. The host-microbe mutualistic relationship operates optimally in healthy conditions and induces strong protective responses against foreign pathogens (Y. and Belkaid, 2015). Dendritic cells (DCs) and T cells are important components of innate and adaptive immune systems respectively. Dendritic cells present antigens to T cells and endow the differentiation of effector T cells. Microbes in the gut are directly and indirectly involved in DC cell activation or effector T cell differentiation/regulation preventing mucosal infection. It has been found that short-chain fatty acid (SCFAs)-C2, C3, C4, C5 fermented products of digestible resistant dietary fibres are produced by the anaerobic microbiota in the colon. These SCFAs involve in the regulation of DC, T cells’ function and developing protective immunity. It has been reported that SCFAs control the effector T cell function by activating or suppressing the FoxP3 Treg (forkhead box P3T regulatory) cells’ transcription. Park et al. reported that in cases of high T cell activation, SCFAs activate the histone deacetylase (HDAC), downregulating the transcription of the FoxP3 Treg gene. In contrast, under low T cell activation, SCFAs inhibit HDAC, upregulating the transcription of the FoxP3 Treg gene. Thus, microbiome-produced SCFAs can control both effector and regulatory cells function, which is crucial to boost immunity against pathogens (Purusawa et al., 2017; Park et al., 2015).

Several studies reported that alteration in host-microbe interactions/bacterial dysbiosis disrupts the host cells’ homeoeostasis leading to the evolution of malignancy (Sobhani et al., 2011; Weir et al., 2013). C. Xuan observed that breast tissues with microbial dysbiosis cause lower expression of immune sensors like TLR 2,5,9. Reduction in expression of antimicrobial response effectors: interleukin-12 A (IL-12A), myeloperoxidase (MPO) and bactericidal/permeability-increasing protein (BPI) was also observed, as compared to healthy breast tissues. In conclusion, bacterial dysbiosis causes inhibition of immune sensors and progression of malignancy (Xuan et al., 2014).

Researchers also reported that immune cell hyperactivation/evasion by bacteria develops cancer. Microbial ligands like LPS (lipopolysaccharides), lipopeptides, lipoteichoic acids, peptidoglycans, flagellins, etc., bind with specific TLR. Following successful binding, various cascade signalling pathways regulating cell proliferation or apoptosis, cell differentiation, secretion of inflammatory cytokines like interferons (IFNs), TNF-α, interleukins (IL1, IL6, IL8, IL12, IL16), etc., are affected (Ernst and Chandler, 2017; van Bergenhenegouwen et al., 2016; Schirbel et al., 2013). The hyper-activation of TLRs or escaping immune recognition can lead to cancer development, as illustrated in Fig. 3. Ye et al. showed that gram-negative bacteria like E.coli causes outgrowth and uncontrolled metastasis in non-small cell lung cancer (NSCLC). Overactivation of TLR4 and TLR9 related with lipid synthesis was observed in vitro and in vivo, suggesting immune receptor overactivation by bacterial infection (Ye et al., 2016).

The bacterial outer surface contains complex antigenic moieties, allowing escape immune recognition (by modifying the surface antigens) survival. For example, gram-negative bacteria like Shigella, Neisseria, etc., contain a polysaccharide-rich capsule to escape immune recognition. This immune escape mechanism protects them from phagocytosis and prevents complement activation, ensuring survival within host cells, leading to inflammation (Paciello et al., 2013; Sivagnanam et al., 2010). Bacteria can also dampen immune recognition by acquiring mutation on their surface flagellin. TLR-5 recognizes a conserved motif named dD1a. Several bacteria like Salmonella, Vibrio contain these conserved domains. It has also been reported that the highly virulent Helicobacter has a mutation in the D1 domain of its flagellin Fl1A, which helps in evading immune recognition by TLR-5 and progresses gastric carcinoma (Il Yoon et al., 2012; Pachathundi-kandi et al., 2019). Salmonella typhimurium was also reported to have modified lipid A, inhibiting the TLR4 mediated immune activation. These immune-escaping mechanisms secure the residence within host organisms for a more extended period, allowing pathogenic bacteria modify host cell integrity and signalling cascade triggering cellular malignancies (Kawasaki et al., 2005).

In addition to innate immune evasion/hyperactivation, bacterial infections can also modulate the adaptive immune response in host cells. Adaptive immune responses become activated through secretion of cytokines, activation and proliferation of effector T cells and B cells. Cytolytic activity of effector T cell (CD8+ T cell) and antibodies produced by B cells contributes to killing bacterial pathogens. Pro-inflammatory cytokines like TNF- α, IL-1,8,12 are crucial to clear the bacterial infection from host cells (Duque and Descoteaux, 2014a). Some bacterial pathogens evolve their intracellular mechanism to modulate cytokine production and inhibit B/T cell activation inside host cells. Researchers reported that mycobacterium infected macrophages produce anti-inflammatory cytokines IL-6 inhibiting the activation of effector T cells. The secretion of immunosuppressive cytokines IL-10 was also observed. IL-10 suppresses macrophages and inhibits specific immune responses like MHC-II (major histocompatibility complex) antigen presentation, CD86 costimulatory signals. Activation of Treg cells, down-regulating the immune response has also been observed. All the above observations confirm that bacterial infections manipulate innate and adaptive immune responses in the host stimulating pathogenesis (Jung et al., 2017; Giacomini et al., 2001).

2.3. Genomic instability

Genomic stability is essential for maintaining cellular integrity and protecting cells from: a) DNA replication error, b) oxidative stress (resulting from metabolic by-products), c) various exogenous...
carcinogenic agents causing DNA damage, etc. Genomic instability initiates and progresses carcinogenesis. The baseline mutations are insufficient for developing multiple changes in the host cell genome leading to cancer development. A spontaneous mutation obtained by the host cell induces malignancy leading to metastasis (Van Zijl et al., 2011). The bacterial genotoxins like cytolethal distending toxin (CDT, produced by certain gram-negative bacteria, e.g., *Helicobacter pylori* (Toller et al., 2011), colibactin (produced by *E. coli* (Cuevas-Ramos et al., 2010), and endonucleases (produced by *N. gonorrhoea* (Weyler et al., 2014)) induce DNA damage, favoring genomic instability and oncogenic transformation.

CDT is a protein toxin comprising of three subunits- CdtA, CdtB, and CdtC, encoded by different genes present in one operon. The subunits CdtA and CdtC ensure the binding of CDT to the target cell plasma membrane, and CdtB catalyzes the induction of double-stranded DNA breakage. After shielding the attachment by CdtA and CdtC, CDT endocytoses into the target cells. Following endocytosis, CdtB goes through Endosome-Golgi retrograde transport to the endoplasmic reticulum and translocates into the nucleus. CdtB then instigates double-stranded DNA break, seeking DNA damage response. This response induces G1-S and G2-M cell cycle arrest, responsible for DNA damage and prolongs the accumulation of genetic mutation. The DNA damage response also enhances the mitogen-activated protein kinase (MAPK) function by activating the neuroepithelial cell-transforming gene 1 protein (NET1). The GTPase RhoA leads to more prolonged survival of infected cells, as illustrated in Fig. 4. As a result, the infected cells acquire genetic mutation leading to malignancy (Dixon et al., 2015; Boesze-Battaglia et al., 2016; Guidi et al., 2013). In addition to CDT, certain *E. coli* strains secrete colibactin, which induces DNA double-stranded break, causing genomic instability. The DNA damage activates DNA damage checkpoint pathways ATM (ataxia-telangiectasia, mutated), CHK1 (check point kinase 1), and CHK2 (check point kinase 2), resulting in G2-M cell cycle arrest and chromosomal instability. All these factors lead to the development of cancer (Cuevas-Ramos et al., 2010; Bezine et al., 2014).

### 3. Bacterial infections mediate the progression of cancer

Bacterial inflammation is one of the crucial factors leading to cancer progression. The amplified inflammation, resulting in enhanced cell division, leads to cancer (Cruz and Balkwill, 2015; Domingo-Gonzalez et al., 2017; Korniluk et al., 2017). Researchers found bacterial infection to be carcinogenic and tumour stimulating, leading to the progression of malignancy. In addition, bacterial infections cause genomic instability and produce toxins hampering the regulatory signals associated with cell growth and proliferation (Rubinstein et al., 2013; Sugimoto et al., 2011; Cuevas-Ramos et al., 2010). Bacterial infections and their effects associated with various cancers are represented in Fig. 5. All bacterial strains are not carcinogenic, but few of them are. Examples: *Helicobacter pylori* cause gastric cancer (Stein et al., 2017), *S. typhi* develops gall-bladder carcinoma (Scanu et al., 2015). Other bacterial strains are also found to be linked with cancer. Examples include *Campylobacter jejuni* (associated with small intestinal lymphomas) (He et al., 2019), *Mycobacterium tuberculosis* (associated with lung cancer) (Yamaguchi et al.,...
2020), and *Citrobacter rodentium* (associated with human colorectal cancer) (Umar, 2012).

Some well-known cancer-causing bacteria, major virulence factors, and alterations in the host micro-environment with infections are listed below in Table 1. Although researchers have explored the association between bacterial infections and cancer, bacteria’s role in causing cancer and factors leading to metastasis are not very well understood. There is an excellent scope for future research to study how bacteria act as mediators of rapid progression and cancer metastasis.

### 3.1. Gastric cancer

Gastric cancer is associated with a gram-negative bacterium: *Helicobacter pylori* (*H. pylori*), colonizing the human stomach. Approximately 1089,103 new cases and 768,793 new deaths due to stomach cancer were reported globally in 2020 (Sung et al., 2021; Mentis et al., 2019). Most of the person infected with *H. pylori* do not show any clinical symptoms, but the long-term infection causes inflammation of gastric epithelium. Approximately 10% of infected patients develop peptic ulcers, while 1–3% develop gastric adenocarcinoma. *H. pylori* infection can modulate host cells’ signal transduction and metabolic pathways, including glycolysis, TCA cycle, and amino acid metabolism. The genetic heterogeneity of *H. pylori* influences its virulence factors which plays a crucial role in the pathogenesis of gastric cancer (Zhang et al., 2017; Sgouras et al., 2015; Matsunaga et al., 2018). Cytotoxin-associated gene A (CagA) and peptidoglycan are a few of the various virulence factors of *H. pylori* that penetrate the infected gastric epithelial cells and potentially trigger oncogenic pathways. CagA is a 120–140 kDa protein present in the DNA insertion element. Cag pathogenicity island (cagPAI) induces malignancy by translocating into the host cells. After translocation, CagA is phosphorylated by two tyrosine kinase Abl and Src (cytoplasmic tyrosine kinase) on tyrosine residue at four distinct glutamate-proline-isoleucine-tyrosine-alanine (EPIYA) motifs present at the C-terminal region of the protein, inducing cell migration (Chen et al., 2016; Krisch et al., 2016; Epiya-motifs, 2019; Stein et al., 2002). Along with the CagA protein, peptidoglycan is also transmitted into host cells, triggering the nucleotide-binding oligomerization domain-containing protein 1 (NOD1) dependent nuclear factor kappa light chain enhancer activated B cells (NF-κβ) mediated inflammation leading to chronic inflammation in gastric epithelial cells. Inside the host cells, peptidoglycan can activate the phosphoinositide-3-kinase–protein kinase B/Akt (PI3K-PKB/Akt) signalling in an Src-EGFR (epidermal growth factor receptor) dependent pathway that induces cell proliferation, migration/metastasis, and apoptosis prevention, leading to carcinoma, (Viala et al., 2004; Suarez et al., 2015; R.C. Migration, and Apoptosis By Activation of Pi3K Signaling 2010).

Cyclooxygenase-2/prostaglandin E2 pathway and IL-1β are other critical factors that induce chronic active gastritis and adenocarcinoma (Zhang et al., 2017; Echizen et al., 2016). Fig. 6 shows the schematic illustration of cancer development and progression by CagA and peptidoglycan from *H. pylori*.

E-cadherin is an epithelial adhesion protein that maintains proper cellular barriers associated with p120, β-catenin, and cytoskeletal components. Following *H. pylori* infection translocated CagA binds with
E-cadherin and forms the complex E-cadherin-β-catenin. The impaired function of E-cadherin loosens the epithelial junction and enhances the nucleo-cytoplasmic accumulation of β-catenin, activating the β-catenin-dependent carcinogenesis. Downregulation of β-catenin enhances the cytoplasmic/nuclear expression of p120, which further interacts with Ras-related C3 botulinum toxin substrate 1 (Rac1), p21-activated kinases (PAKs), Rho GTPases (Ras homologue family member A guanosine triphosphatase) and upgrades cellular motility and metastasis (Hu et al., 2018; Oliveira et al., 2009; Li et al., 2015). A high level of reactive oxygen species with *H. pylori* infection in gastric cells fuels the DDBs (DNA double-stranded breaks), DSBs (DNA single-stranded breaks), and impaired cell cycle checkpoint function, further leading to the development of malignancy (Shi et al., 2019).

### 3.3. Oral cancer

Oral cancer, also called oral squamous cell carcinoma (OSCC), originates from the oral mucosa. Nearly 377,713 new cases and 177,757 new deaths due to cancer in the lips and oral cavity were reported globally in 2020 (Sung et al., 2021). The oral cavity homes more than 700 bacterial species, and bacteria like *Fusobacterium, Dialister, Peptostreptococcus, Filifactor, Peptococcus, Catonella*, and *Parvimonas* were associated with oral squamous cell carcinoma (Ferlay et al., 2019; Chattopadhyay et al., 2019; Zhao et al., 2017).

The bacteria interact with oral mucosa by binding with toll-like receptors (TLRs). These bacterial-host cell interactions induce chronic inflammation in the oral cavity by secreting IL-6 (interleukin-6), NF-κB (nuclear factor-κB), IL-8 (interleukin-8). In addition to these, upregulation of the cell survival factors: MYC (Master Regulator of Cell Cycle Entry and Proliferative Metabolism), JAK1 (Janus kinase 1), STAT-3 (Signal transducer and activator of transcription 3) and mesenchymal transition markers: ZEB 1 (zinc finger E-Box binding homeobox 1), TGF-β (transforming growth factor β) were observed. These factors drive cell survival, proliferation, invasion, metastasis, and development of oral carcinoma (Harrandah et al., 2021; Gallimidi et al., 2015). Several causative factors, like tobacco, alcohol, etc., also alter the oral cavity’s microbial composition, influencing microbial dysbiosis and making oral mucosa susceptible to carcinoma (Børtning et al., 2017).

### 3.4. Colon cancer

The human gastrointestinal tract (GIT) contains a diverse microorganisms called the intestine’s normal microflora. Almost 1148,515 new cases and 576,858 new deaths due to colon cancer were reported in 2020 across the globe (Sung et al., 2021). Approximately 100 trillion bacteria are present in the human gut. These microflorae control the intestine’s homoeostasis by regulating metabolic functions, developing immunity, and preventing pathogenic attacks (Gensollen et al., 2016; Claesson et al., 2012; Gagnié et al., 2016). However, when these flora’s regular population alters (bacterial dysbiosis), it results in pathogenic conditions like cancer. The colon is the most heavily bacterial-populated part of GIT and is 12 folds more prone to cancer than the small intestine (Gagnié et al., 2016).

*Fusobacterium nucleatum* is a harmful gram-negative bacteria, generally found in the oral cavity and associated with colorectal cancer. *F. nucleatum* has a highly conserved adhesion protein FadA that binds to E-cadherin and activates β-catenin signalling. This further triggers the inflammatory genes NF-κB, pro-inflammatory cytokines like IL-6, IL-8, and IL-18 in the colon epithelial cells inducing colorectal cancer (CRC) (Rubinstein et al., 2013). Furthermore, *Fusobacterium nucleatum* was also

---

**Fig. 5. Various cancers associated with bacterial infections.** Bacteria infects the host cell and ensure their prolonged survival by modulating the host cell machinery; NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), IL (interleukins), ROS (reactive oxygen species), STAT-3 (signal transducer and activator of transcription 3).
reported to enhance tumour multiplicity by recruiting tumour-infiltrating myeloid cells that promote colorectal malignancy (Kostic et al., 2012).

Some E.coli strains (B2 E.coli 11G5) can produce cyclomodulins/ genotoxins, breaking host cells’ DNA and inducing colorectal cancer. In addition, these bacterial strains can induce inflammation, cause colon epithelial damage, enhance cell proliferation, progress colonic neoplasia (Raisch et al., 2014; Buc et al., 2013). Furthermore, various other bacteria like Streptococcus galalfluidicas (ex S. bovis) (Amado et al., 2015), Enterococcus faecalis (Escolà-Vergé et al., 2020), Clostridium septicum (Nanjappa et al., 2015) were also found to be associated with colorectal carcinoma.

### 3.5. Breast cancer

A diverse population of bacteria exists in breast tissue irrespective of lactation. Around 22261,419 new cases and 684,996 new deaths due to breast cancer were reported globally in 2020 (Sang et al., 2021). Proteobacteria and Firmicutes (mainly the class Bacilli) are the primary species found in breast cells. Breasts, being fatty tissues with wider vasculature, support bacterial growth. Bacterial composition plays an essential role in building immunity in neonates (Urbaniaik et al., 2014). The commensal bacteria in the human body plays a vital role in maintaining the various physiological functions, but microbial dysbiosis induces inflammation leading to cancer. The increased bacterial population (high abundance of genus Alistipes) in the nipple was reported to progress breast cancer by modulating therapeutic responses (Chan et al., 2016).

Bacillus, Enterobacteriaceae, and Staphylococcus were found in great numbers in breast cancer tissues. These bacteria caused DNA double-strand breaks in HeLa cells (Chan et al., 2016). They were also found to progress breast cancer by modulating therapeutic responses (Chan et al., 2016).

### 4. Role of bacterial pathogens in epithelial to mesenchymal transition (EMT) leading to metastasis

Epithelial cells act as a functional interface between adjacent cells of...
our body distinguishing different organs. These cells are tightly bound to their surrounding cells and basement membrane by multiple junction proteins like tight junctions, adherens junctions, desmosomes, and hemidesmosomes (Farquhar and Palade, 1963). However, the epithelial barrier loses its static phenotype during the developmental process, fibrogenesis or tumorigenesis and gains drastic migratory behaviour, leading to metastasis (Jechlinger et al., 2003). Loss of tight junction proteins cadherin/E-cadherin, cytokeratin and gain of vimentin, matrix metalloprotease, fibronectin and integrin αvβ3 are the characteristics of EMT (Lamouille et al., 2014). Multiple kinase-mediated signalling pathways like TGFβ−1/Smad2/3, Wnt/Notch, Ras>Raf>Mek>Erk>NF-κ B signalling contribute majorly to initiate the EMT and metastasis (Zhang et al., 2016; Olea-Flores et al., 2019).

Although the microbes are crucial in protecting host cells, an alteration in their composition and distribution disrupts homeostasis in host cells. This altered relation favours inflammatory disorders promoting EMT (Y. and Belkaid, 2015). The bacterial lipopolysaccharide (LPS), a major component of gram-negative bacteria’s outer membrane, induces EMT. TGF β1 is one of the most potent instigators of EMT and liver fibroblast. Smad 2/Smad 3 are the direct downstream signalling molecules in the TGF β1 transduction pathway. Activated TGF β1 receptor induces Smad2/3 phosphorylation forming a heteromeric complex with Smad 4. This complex further translocates to the nucleus for regulating specific gene expression (Schiffer et al., 2000). Zhao et al. demonstrated that stimulation of human intrahepatic biliary epithelial cells (HIBEpCs) with LPS resulted in phenotypic changes producing bipolar cells with fibroblastic morphology. Downregulation of E-cadherin and upregulation of mRNA along with protein expression of TGF β1 were also observed. The expression of mesenchymal markers like S100A and α-SMA (α-smooth muscle actin) was also increased significantly. Their study concluded that LPS triggers EMT via TGF β1/Smad 2/Smad 3 pathway (Zhao et al., 2011).

Loss of epithelial polarity is one of the major hallmarks of EMT and cancer metastasis, as illustrated in Fig. 7. Transcriptional repressor Snail acts as a potent inducer of EMT suppressing E-cadherin transcription/expression. Lee et al. showed that infections with cytotoxin-associated gene A (CagA) positive H. pylori strain 60,190 downregulate the epithelial tight junction protein E-cadherin in gastric cancer cells with increased tyrosine phosphorylation. The glycogen synthase kinase 3 (GSK 3) is a serine/threonine kinase that induces proteasomal degradation of oncopgenic protein Snail, c-Myc (cellular myelocytomatosis oncogene), Mcl-1 (induced myeloid leukaemia cell differentiation protein). The CagA infections showed the destruction of GSK 3 (glycogen synthase kinase 3), confirming the stability of Snail protein and down-regulation of E-cadherin, leading to EMT. The CagA induced excessive cellular transformation with cell motility, scattering, and metastasis known as ‘hummingbird phenotype’ was also observed. CagA was also found to induce in-vivo invasive progression of non-invasive MCF-7 cells. The cells crossed the basement membrane in the chick chorioallantoic membrane (CAM) assay (Lee et al., 2014).

Chow et al. exhibited that incubation of non-small lung cancer (NSCLC) cells with heat-inactivated E.coli elevated cell adhesion, proliferation, migration and metastasis via TLR4 (toll-like receptor 4) signalling. TLR4 is a pathogen recognition receptor. Incubation of NSCLC cells with heat-inactivated E.coli showed the inhibition of TLR4, leading to the malignant progression of non-invasive MCF-7 cells. Cag A, phosphorylated by Abl and Src tyrosine kinase on tyrosine motif EPIYA (glutamate-proline-isoleucine-tyrosine-alanine) induces cellular proliferation. Peptidoglycan (glutamate-proline-isoleucine-tyrosine-alanine) of H. pylori triggers signalling pathways leading to cancer progression. Cag A, phosphorylated by Abl and Src tyrosine kinase on tyrosine motif EPIYA (glutamate-proline-isoleucine-tyrosine-alanine) induces cellular proliferation. Peptidoglycan induces proliferations, metastasis, inhibition of apoptosis by activation of NOD1- NF-κ B (nucleotide-binding oligomerization domain-containing protein one-nuclear factor kappa light chain enhancer activated B cells), PI3K-PKB/Akt(phosphoinositide-3-kinase–protein kinase B/Akt), Src-EGFR (epidermal growth factor receptor) signalling pathway.

Fig. 6. Cytotoxin-associated gene A (Cag A) and peptidoglycan of H. pylori triggers signalling pathways leading to cancer progression. Cag A, phosphorylated by Abl and Src tyrosine kinase on tyrosine motif EPIYA (glutamate-proline-isoleucine-tyrosine-alanine) induces cellular proliferation. Peptidoglycan induces proliferations, metastasis, inhibition of apoptosis by activation of NOD1- NF-κ B (nucleotide-binding oligomerization domain-containing protein one-nuclear factor kappa light chain enhancer activated B cells), PI3K-PKB/Akt(phosphoinositide-3-kinase–protein kinase B/Akt), Src-EGFR (epidermal growth factor receptor) signalling pathway.
Wiele et al. also deciphered certain quorum sensing peptides produced by bacteria like Phr0662 (*Bacillus sp*.), EntF metabolite (*Enterococcus faecium*), and EDF-derived (*Escherichia coli*) peptides interact with mammalian cells leading to cancer metastasis. It was observed from multiple confirmation assays that bacterial quorum sensing peptides activate the Ras/raf/MEK/MAPK, PI3K/Akt, STAT intracellular signaling cascades in mammalian cells, leading to genetic alterations and cancer metastasis. Hyper phosphorylation of epidermal growth factor receptors (EGFR) and activation of Smad2/Smad3 protein linked with cell cytoskeleton rearrangement and cell migration were also noticed. Histidine 4 (HIST1H4) protein is a well-known histone protein associated with increased Notch 1 stimulation, NF-kB production, contributing to cell proliferation, angiogenesis and metastasis. In the presence of bacterial quorum sensing peptide upregulation of HIST1H4 was observed. All these observations confirm that bacterial infections can lead to uncontrolled metastasis in mammalian cells through activation of several signalling cascade mechanisms (Van De Wiele et al., 2015).

5. Application of bacteria for cancer therapy

Cancer is neither a transmissible disease nor an infectious disease, but bacterial infections increase the chances of cancer development. Though conventional cancer therapies like radiotherapy, chemotherapy, etc., has been exceptional in improving survival rates over the years, there are several drawbacks and limitations. Bacteriotherapy, the application of bacteria for therapeutic purposes, is a novel strategy to overcome the limitations of conventional therapy and offers effective cancer therapy. Bacteriotherapy can be used as a stand-alone therapy or in combination with conventional therapies. The application of bacteria for the delivery of therapeutics, genes, and drugs broadens its application in cancer therapy. Researchers demonstrated the successful application of bacteriotherapy for regression of tumours and inhibition of metastasis (Riglar and Silver, 2018; Enejiyon et al., 2020; Yan et al., 2015). Examples of few bacteria used for cancer therapy are *E.coli* (Yan et al., 2015), *Salmonella* (Gao et al., 2020), *Pseudomonas* (Chang et al., 2015), *Bifidobacterium* (Parisa et al., 2020), and *Lactobacillus* (Sentürk et al., 2020). Table 2 lists the summary of bacteriotherapy for cancer treatment.

In this part of the review, the application of bacteria for drug delivery, immunotherapy, and combinational therapeutic approaches are discussed in detail.

5.1. Drug delivery

Poor vascularization and high interstitial fluid pressures are the characteristics of solid tumours, hindering the penetration of anticancer drugs into the tumour core and reducing their efficacy. Several drug carriers like liposomes, micelles, etc., accumulate in the perivascular region following their leakage from the vasculature. However, the released drug still does not penetrate the hypoxic tumour core due to the absence of arteries and high interstitial fluid pressure (Muthu et al., 2014; Ogihara, 2013). Bacteria can be one of the robust platforms for anticancer drug delivery under both *in-vitro* and *in-vivo* conditions, as shown in Fig. 8. Research shows that bacterial species like *S. typhimurium* (Yu et al., 2012), *E. coli Nissle 1917 (EcN)* (Stritzker et al., 2007) can colonize and proliferate in the tumour’s hypoxic region. Therefore, bacteria and bacteria-derived cells can be emerging carriers for targeted drug delivery applications. Zhang et al. designed and developed a drug delivery vehicle by genetically engineering *E. coli Nissle 1917 (EcN)* with pHILP (pH-(low)-insertion-peptide). The *in-vitro* and *in-vivo* experiments showed doxorubicin-loaded minicells-pHILP
Various bacteria used for cancer therapy and their significant outcome post-treatment.

| Bacterial strain | Treated cancer cell line | Significant outcome | References |
|------------------|--------------------------|---------------------|------------|
| *E. coli* Nissle 1917 (EcN) | MCF-7, 4T1 (Breast cancer cell) | Rapid internalization and drug release in the tumour's hypoxic region; significant tumour regression; no adverse effects. | (Zhang et al., 2018) |
| *Salmonella enterica* | K1775, B16F10 (murine melanoma), 4T1 (murine breast cancer). | Enhanced tumour-intracutaneous communication & chemo sensitization. | (Chang et al., 2013) |
| *Salmonella enterica* | B16F10 (mouse melanoma) and 4T1 (mouse breast cancer). | Reduced expression of immune tolerance helping rate-limiting enzyme indolesamine 2, 3-dioxygenase 1 (IDO), phospho-protein kinase B (P-AKT), phospho-mammalian target of rapamycin (P-mTOR), and phospho-p70 ribosomal S6 kinase (P-p70s6K), tumour cell lysis. | (Kuan and Lee, 2016) |
| *Listeria monocytogenes* | 501 Mel, A375, and SK-Mel-28 melanoma cells. | Enhanced ROS production; activated caspase-3 dependent apoptosis of tumour cells; increased cytokines (e.g., IL-2), differentiation of CDB+ 7 T cells; and inhibited metastasis and tumour cell growth. | (Vitiello et al., 2019) |
| *E. coli* MG1655 | CT26 (colon), RENCA (renal), and TRAMPCI1 (prostate) cancer cell | Secretion of TNF-α, IL-12, IL-6, and IL-10; inhibition of cancer cell proliferation and metastasis. | (Murphy et al., 2017) |
| *Bifidobacterium breve* UCC2003 and *Clostridium difficile* CCUG 37,780 | A549 (lung cancer cell). | Rapid delivery of hypoxic-region-specific anti-cancerous nanomaterials; inhibition of epidermal growth factor receptors, and HIF-1α (hypoxia-induced factor); regression of tumour growth. | (Luo et al., 2016) |
| *Clostridium perfringens* | Caco-2 (colon adenocarcinoma), MDA-MB-231 (mammary adenocarcinoma), OE-33 (oesophageal adenocarcinoma) | Dysregulated expression of claudin-3,4 and 7; increased apoptosis; significant tumour cell killing. | (Becker et al., 2018) |

Bacterial strain | Treated cancer cell line | Significant outcome | References |
|-----------------|--------------------------|---------------------|------------|
| *S. typhimurium* | A1-R | Inhibition of vascular endothelial growth factor (VEGF) and angiogenic; prevents metastasis and tumour growth. | (Hiroshina et al., 2014) |
| *Streptococcus pyogenes* | HROG02, HROG05 and HROG10, ADI and Palomid 529 (glioblastoma cell) | Induction of apoptosis, inhibition of proliferation and cancer cell growth. | (Fiedler et al., 2015) |
| *Lactococcus lactis* | SW480 (colon cancer epithelial cell) | Cytotoxic effects on colorectal cancer cells; apoptosis induction by increasing the bax/bcl-2 ratio in both mRNA; protein levels and induction of pro-apoptotic stress protein CHAC1 (cation transport regulator-like protein 1); cell cycle arrest; tumour growth inhibition. | (Ahmadi et al., 2017) |
| *Bacillus subtilis* | MCF-7, MDA-MB-231 (breast cancer cell) | Downregulation of MMP-9 (matrix metalloproteinase-9) expression; activation of nuclear factor-κB (NF-κB), activator protein-1 (AP-1); inhibition of phosphorylation of Akt, extracellular signal-regulated kinase (ERK), tumour cell invasion, migration and proliferation. | (Park et al., 2013b) |
| *Clostridium butyricum* MIYAI 588 | 253J-BV cells (human bladder cancer), H460 (human lung cancer), 786-O (human renal cancer), HER293 (human embryonic kidney) and MBT-2 cell lines (murine bladder cancer) | Endogenous release of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), release of cytokines and chemokines, tumour cell lysis. | (Shimbuk et al., 2013) |

selectively targeted the tumour acidic micro-environment. MinicellsHILP were observed to penetrate the tumour core, releasing doxorubicin in a controlled fashion, killing the cancer cells (Zhang et al., 2018).

The bacterial outer membrane can also be used as a drug carrier for targeted cancer therapy. Gujarati et al. used mutant *E. coli* strain to develop outer membrane vesicles (OMVs), loaded with siRNA (model drug) and decorated with human epidermal growth factor receptor 2 (HER2)-specific antibody (targeting ligand). In-vivo studies using siRNA loaded OMVs showed rapid extravasation and accumulation selectively in the tumour tissues. In-vivo anti-tumour efficacy of HER2-targeted, siRNA-carrying OMVs demonstrated that a small amount of siRNA was sufficient for substantial inhibition compared to the non-targeted carrier.
or free siRNA. Further *in-vitro* and *in-vivo* data revealed no non-specific binding, uptake, or toxicity against normal cells (Gujrati et al., 2014).

In addition to the bacterial minicells and OMVs, bacteria-driven microswimmers were developed for target-specific drug delivery. Microswimmers are hybrid microsystems integrated with bacteria that can swim like *Serratia marcescens* (*S. marcescens*), *E. coli* (*E. coli*), etc. The inherent physical and chemical features of bacteria like flagella, chemotaxis and viscoelasticity support micro swimming (Park et al., 2017; Zhuang and Sitti, 2016). Park et al. demonstrated the design and application of bacterial microswimmers for targeted drug delivery. A microswimmer was engineered by attaching a single *E. coli* bacterium to the surface of doxorubicin-loaded polyelectrolyte multilayer (PEM) microparticles embedding magnetic nanoparticles. The *in-vitro* studies demonstrated the drug delivery efficacy of these bacterial microswimmers, suggesting the valuable and significant contribution of bacteria to developing target-specific drug carriers (Park et al., 2017).

5.2. Immunotherapy

Immunotherapy is a powerful strategy to fight cancer and has greater advantages than chemotherapy or radiotherapy. However, the clinical outcome of immunotherapy for various tumours is limited by immune toxicity, recurrence, lack of initial response to therapy, etc. A successful tumour immune response is generated when a) tumour antigens are taken up by antigen-presenting cells (APC like dendritic cells), b) APCs are properly matured to be differentiated further, c) tumour-specific T cells are generated, and d) anti-tumour T cells are infiltrated into the tumour cells (Sagnella et al., 2020). Fig. 9 shows the role of bacterial vectors in activating several immune cells and tumour cell lysis.

Sagnella et al. developed the EnGeneIC Dream Vector (EDV): a bacteria-derived delivery system conjugated with target-specific antibody and loaded with a super cytotoxic drug PNU-159,682 (682). In addition to delivering the drug to the target site, EDV also induces the tumour-specific immune response, triggers the *in-vivo* priming and maturation of dendritic cells within the tumour micro-environment. Up-regulation of tumour-specific CD4+ T cells, CD8+ T cell, CD80, and CD86 in response to clear cancer cells were also detected. Natural killer cells (NK) and interferon-γ (IFN-γ) have the inherent ability to kill the cancer cell by releasing perforin and granzyme. The EDV treatment also resulted in a remarkable production of NK cells, recruitment of IFNs to the target site, lysis of the cancer cells, and inhibition of tumour relapse. Thus, the bacteria-derived vector is indeed a novel and significant contribution to cancer immunotherapy (Sagnella et al., 2020).

Chen et al. designed nanoformulations with bacterial outer membrane vesicles (OMVs) to improve immunotherapy’s efficacy. In this study, OMVs of attenuated *Salmonella* were functionalized with polyethylene glycol (PEG). These functionalized OMVs were loaded with tegafur, a fluorouracil prodrug (5-FU), and were conjugated with tumour-specific ligand Arg-Gly-Asp (RGD) peptide. This nanoformulation was observed to be immune-stimulatory, demonstrated improved blood circulation and tumour specificity. *In-vivo* biodistribution studies showed target-specific accumulation, and histological examinations of the liver, spleen, and kidney showed no pathological abnormalities, indicating biocompatibility. Furthermore, TNF-α, interferon-γ (IFN-γ), interleukin-12 (IL-12), IL-4, IL-17, CD4+, CD8+ T cells were upregulated, resulting in the death of cancer cells and inhibiting metastasis. This study demonstrated that bacteriotherapy could be a valuable strategy for cancer immunotherapy (Chen et al., 2020).

5.3. Combinational therapy

The combination of bacteriotherapy and conventional therapy has shown significant and sustained therapeutic potential. Conventional chemo/radiotherapy is associated with a relapse of tumours and adverse side effects due to their lack of specificity and systemic toxicity.
Bacteria therapy combined with chemo/radiotherapy can be a new approach to overcome these drawbacks. The combination of bacteriotherapy with conventional therapy can prevent cancer cells’ growth, as demonstrated in Fig. 10.

The chemotherapy is limited by high dosages and low penetration, in addition to the poor vasculature and hypoxic micro-environment. Jia et al. demonstrated the improved efficacy of cyclophosphamide (CTX), a chemotherapeutic drug combined with tumour-targeting bacteria *Salmonella* VNP20009. This combinational therapy also showed reduced toxicity and payload of the drug. Also, more bacteria were found to be infiltrated at the tumour region. The vascular endothelial growth factor (VEGF) at the tumour site was also reduced as compared to individual treatments, suggesting the clinical importance of this combined cancer therapy (Jia et al., 2007).

Another dominant problem in chemotherapy is the development of drug resistance. P-glycoprotein 1 (P-gp) is the multidrug resistance protein 1 (MDR1) present on the plasma membrane, fluxing out chemo drugs. The expression of P-gp is controlled by phospho-protein kinase B (P-AKT), phospho-mammalian targets of rapamycin (P-mTOR), and phospho-p70 ribosomal s6 kinase (P-p70s6K). *Salmonella* with a chemo drug (5-Fluorouracil) was observed to downregulate P-gp by inhibiting the protein kinases, making the cancer cells sensitive to chemo drug. This finding demonstrates that the bacteria combined with chemotherapy could prevent drug resistance and improve cancer therapy (Yang et al., 2018).

In addition to chemotherapy, the application of bacterial vectors also improved radiotherapy. Jiang et al. designed a cytotoxic protein cytolysin A (ClyA) producing *E. coli* strain K-12 and combined it with radiotherapy. Individual treatments resulted in reduced tumour growth, but re-growth of tumours was observed post-treatment. The novel combined therapy (*E.coli*-radiotherapy) reduced tumour growth and metastasis in colon cancer significantly, depicting the significance and efficacy of combinational treatment (Jiang et al., 2010).

6. Conclusions

Bacteria inhabited in our body plays a vital role in a) maintaining the digestive system’s normal physiological health (intestine, colon, stomach), b) protecting the immune system and c) preventing the colonization of pathogens. However, an imbalance in these organisms, i.e., bacterial dysbiosis, modulates several host cellular signalling pathways, leading to cancer development, eventually causing death. In this review, we have discussed several inherent bacterial characteristics that can trigger carcinogenesis. *H.pylori* containing cagPAI can activate PI3K-Akt kinase pathway, increase oxidative stress, cause disruption of E-cadherin/β-catenin/p120 interactions, damage host cell DNA, and develop gastric cancer. Bacterial dysbiosis can be associated with several cancers.
(oral cancer, colon cancer, and breast cancer) due to excessive ROS generation, genomic instability, inhibition of apoptosis and excessive cell proliferation.

Researchers, over the years, have successfully understood several mechanisms like chronic inflammation, immune system evasion, and genomic instability, triggering cancer. Bacterial dysbiosis can modulate the host cell signalling by enhancing the secretion of several pro-inflammatory cytokines like NF-κβ, IL-6, IL-8, IL-10, IL-18, etc. NF-κβ is the central player of inflammation/chronic inflammation, instigating hyper-proliferation of host cells leading to cancer. These inflammatory cytokines are also indirectly associated with a high level of free radicals and DNA mutations, enhancing chronic inflammation by damaging proteins and cell membranes. Bacterial infections also provoke malignancy by their surface modification, immune receptor activation/evasion forming DNA double-strand break, and genomic instability by secreting genotoxins (CTD). Though researchers have linked bacterial infections and cancer, the number of bacterial-mediated host cell transformations leading to cancer development is enormous than reported. Furthermore, it is crucial to understand the association between bacterial infections and cancer to develop alternative and novel therapeutic approaches.

Bacterial infections lead to cancer progression by various mechanisms, but bacteria significantly improve cancer therapy when applied as a vector or drug carrier. Bacterial minicells, microswimmers, and outer cell membrane vesicles (OMV) deliver the drug into the tumour’s hypoxic region, resulting in tumour regression. Bacterio-immunotherapy is emerging as an important therapeutic approach addressing the immunotherapy mediated toxicity and recurrence of tumours. The combinational therapy of bacteria and chemo/radiotherapy is also evolving as a dominant scheme for overcoming the limitations of conventional treatment. Furthermore, there is a great need for understanding the mechanism by which bacteria targets, penetrates, and colonizes the tumour. This understanding would lead to the development of more effective treatment strategies. Research on the application of bacteria in combinational with conventional treatment can open up a new door for researchers to develop safe, biocompatible, and target specific cancer therapies.

CRediT authorship contribution statement

Sajmina Khatun: Data curation, Formal analysis, Writing – original draft, Writing – review & editing. Tejaswini Appidi: Data curation, Formal analysis, Writing – original draft, Writing – review & editing. Aravind Kumar Rengan: Resources, Writing – review & editing.

Declaration of Competing Interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge Dept. of Science & Technology (DST), Dept. of Biotechnology (DBT), Govt. of India for research funding of DST-Inspire (DST/INSPIRE/04/2015/000377), DST-AMT (DST/TDT/AMT/2017/227(G)), DBT-NNT (BT/NNT/28/1386/2017) projects. The authors also acknowledge the financial support by Vasudha foundations, Hyderabad, India. Author SK acknowledges University Grants Commission (UGC), Govt. of India for UGC-JRF fellowship (18-340769). Author TA acknowledges Dept. of Science & Technology (DST), Govt. of India for Inspire fellowship (IF160291).
References

Abalter, M.C., Schubert, M., Götz, C., Schmidt, T.P., Poselger, W., Wessler, S., 2016. HTRA-
medinted E-cadherin degradation is limited to Degr and Degr homologs expressed as
gram-negative pathogens. Cell Commun. Signal. 14, 1–12. https://doi.org/10.1186/s12961-
016-0153-y.

Afzalri, Z.K., Zhou, Y.H., Fleischman, A., 2015. Chronic inflammation: is it the driver or
is it the driving road for dormant transformation. Genes Cancer. 6, 214–219. https://doi.org/
10.18632/gncancer.64.

Ahmadi, S., Ghollasi, M., Hosseini, H.M., 2017. The apoptotic impact of nisin as a potent
Chattopadhyay, I., Verma, M., Panda, M., 2019. Role of oral microbiome signatures in
Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D.,
Abfalter, C.M., Schubert, M., Gornigen, D., Ren, B., Pickard, R., Li, J., Ozer, E., Hartmann, E.M., Xiao, W., Tickle, T.,
SC. Chow, S.D. Gowin, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
M.C. Chow, S.D. Gowing, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
Ahmadi, S., Ghollasi, M., Hosseini, H.M., 2017. The apoptotic impact of nisin as a potent
Chattopadhyay, I., Verma, M., Panda, M., 2019. Role of oral microbiome signatures in
Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D.,
Abfalter, C.M., Schubert, M., Gornigen, D., Ren, B., Pickard, R., Li, J., Ozer, E., Hartmann, E.M., Xiao, W., Tickle, T.,
SC. Chow, S.D. Gowin, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
M.C. Chow, S.D. Gowing, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
Ahmadi, S., Ghollasi, M., Hosseini, H.M., 2017. The apoptotic impact of nisin as a potent
Chattopadhyay, I., Verma, M., Panda, M., 2019. Role of oral microbiome signatures in
Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D.,
Abfalter, C.M., Schubert, M., Gornigen, D., Ren, B., Pickard, R., Li, J., Ozer, E., Hartmann, E.M., Xiao, W., Tickle, T.,
SC. Chow, S.D. Gowin, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
M.C. Chow, S.D. Gowing, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
Ahmadi, S., Ghollasi, M., Hosseini, H.M., 2017. The apoptotic impact of nisin as a potent
Chattopadhyay, I., Verma, M., Panda, M., 2019. Role of oral microbiome signatures in
Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D.,
Abfalter, C.M., Schubert, M., Gornigen, D., Ren, B., Pickard, R., Li, J., Ozer, E., Hartmann, E.M., Xiao, W., Tickle, T.,
SC. Chow, S.D. Gowin, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
M.C. Chow, S.D. Gowing, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
Ahmadi, S., Ghollasi, M., Hosseini, H.M., 2017. The apoptotic impact of nisin as a potent
Chattopadhyay, I., Verma, M., Panda, M., 2019. Role of oral microbiome signatures in
Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D.,
Abfalter, C.M., Schubert, M., Gornigen, D., Ren, B., Pickard, R., Li, J., Ozer, E., Hartmann, E.M., Xiao, W., Tickle, T.,
SC. Chow, S.D. Gowin, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
M.C. Chow, S.D. Gowing, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
Ahmadi, S., Ghollasi, M., Hosseini, H.M., 2017. The apoptotic impact of nisin as a potent
Chattopadhyay, I., Verma, M., Panda, M., 2019. Role of oral microbiome signatures in
Buc, E., Dubois, D., Sauvanet, P., Raisch, J., Delmas, J., Darfeuille-Michaud, A., Pezet, D.,
Abfalter, C.M., Schubert, M., Gornigen, D., Ren, B., Pickard, R., Li, J., Ozer, E., Hartmann, E.M., Xiao, W., Tickle, T.,
SC. Chow, S.D. Gowin, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
M.C. Chow, S.D. Gowing, J.J. Cools-lartigue, C.B. Chen, J. Berube, H. Yoon, C.H.F. Chan,
Hiroshima, Y., Zhang, Y., Murakami, T., Maawy, A., Miwa, S., Yamamoto, M., Yano, S., Grebowska, A., Moran, A.P., Matusiak, A., Bak-Romaniszyn, L., Czkwianianc, E., Giacomini, E., Iona, E., Ferroni, L., Miettinen, M., Fattorini, L., Orefici, G., Julkunen, I., Fiedler, T., Strauss, M., Hering, S., Redanz, U., William, D., Rosche, Y., Classen, C.F., Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Pi Farquhar, M.G., Palade, G.E., 1963. Junctional complexes in various epithelia. Science 80- (335), 859.

Hu, G., Guo, L., Ye, G., 2018. Helicobacter pylori infection impairs gastric epithelial barrier function via microRNA-100-mediated mTOR signaling. Oncotarget 9, 5020–5035. https://doi.org/10.18632/oncotarget.24614.

Hu, G., Guo, L., Ye, G., 2018. Helicobacter pylori infection impairs gastric epithelial barrier function via microRNA-100-mediated mTOR signaling. Oncotarget 9, 5020–5035. https://doi.org/10.18632/oncotarget.24614.

Hu, G., Guo, L., Ye, G., 2018. Helicobacter pylori infection impairs gastric epithelial barrier function via microRNA-100-mediated mTOR signaling. Oncotarget 9, 5020–5035. https://doi.org/10.18632/oncotarget.24614.

Hu, G., Guo, L., Ye, G., 2018. Helicobacter pylori infection impairs gastric epithelial barrier function via microRNA-100-mediated mTOR signaling. Oncotarget 9, 5020–5035. https://doi.org/10.18632/oncotarget.24614.
S. Khatun et al. Current Research in Microbial Sciences 2 (2021) 100078

Sentiurk, M., Erkan, F., Yalcin, S., 2020. The secondary metabolites produced by Lactobacillus plantarum downregulate BCL-2 and BFFY genes on breast cancer cell lines. Inhibitory model compound molecule drug discovery approach. Cancer Chemother. Pharmacol. 85, 33–45. https://doi.org/10.1007/s00280-019-03978-6.

Soguras, D.N., Trong, T.T.H., Yamada, Y., 2015. Pathogenesis of Helicobacter pylori infection. Helicobacter. 20, 8–16. https://doi.org/10.1111/hel.12255.

Shi, Y., Wang, P., Guo, Y., Liang, X., Li, Y., Ding, S., 2019. Helicobacter pylori-induced DNA damage is a potential driver for human gastric cancer AGS cells. DNA Cell Biol. 38, 222–280. https://doi.org/10.1089/dcb.2018.04467.

Shine, E.E., Xue, M., Patel, J.R., Healy, A.R., Surovtseva, Y.V., Herzon, S.B., Crawford, J. M., 2018. Model Cobalxins exhibit human cell genotoxicity in the absence of host bacteria. ACS Chem. Biol. 13, 3286–3292. https://doi.org/10.1021/acschembio.8b00714.

Shinnoh, M., Horinaka, M., Yasuda, T., Yoshikawa, S., Morita, M., Yamada, T., Miki, T., Sakai, T., 2013. Clostridium butyricum MIYARI 588 displays antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-B. Int. J. Oncol. 42, 903–911. https://doi.org/10.3892/ijo.2013.2790.

Sgouras, D.N., Trang, T.T.H., Yamaoka, Y., 2015. Pathogenesis of Helicobacter pylori infection. Helicobacter. 20, 8–16. https://doi.org/10.1111/hel.12255.

Teshima, R., Hanada, K., Yamaoka, Y., 2018. Aggregatibacter actinomycetemcomitans activates the cathepsin G pathway in human monocytes and macrophages. Infect. Immun. 86, 81–90. https://doi.org/10.1128/IAI.00858-17.

Vitala, J., Chaput, B., Boccoea, G., Dona, A., Girardin, S.E., Moran, A.P., Athman, R., Momet, S., Huere, M.R., Coyle, A.J., DiStefano, P.S., Sansonetti, P.J., Labigne, A., Bertin, J., Philpott, D.J., Ferrerio, R.L., 2004. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 5, 1666–1714. https://doi.org/10.1038/ni1166.

Vitiello, M., Evangelista, M., Di Lascio, N., Kusmic, C., Massa, A., Orso, S., Sarti, S., Marracci, A., Rodzic, K., Geremili, L., Chandra, D., Salvetti, A., Pucci, A., Tormo, C., Fain, G., Pisa, C., Bruno, S., unpublished data. 2018. Antimicrobial effects of attended Listeria monocytogenes in a genetically engineered mouse model of malaria. Oncogene. 38, 3756–3762. https://doi.org/10.1038/s41388-019-0681-8.

Walkerall, Y.D., Gaidt, R., Nayak, V., 2013. Study on Salmonella Typhi occurrence in gallbladders of patients suffering from chronic cholelithiasis—a predisposing factor for carcinoma of gallbladder. Diagn. Microbiol. Infect. Dis. 77, 69–73. https://doi.org/10.1016/j.diagmicrobio.2013.05.014.

Wang, S., Deng, W., Liu, L., Xu, M., Wang, Y., Liu, T., Zhang, Y., Wang, B., Cao, H., 2019. Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis. Mol. Carcinog. 58, 1155–1167. https://doi.org/10.1002/mc2.2999.

Weir, T.L., Manter, D.K., Sheflin, A.M., Barnett, B.A., Heuberger, A.L., Ryan, E.P., 2013. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE 8. https://doi.org/10.1371/journal.pone.0070803.

Weyler, L., Engelbrecht, M., Forsberg, M.M., Brehwens, K., Vare, D., Vielfort, K., Wojcik, A., Aro, H., 2014. Restriction endonucleases from invasive Neisseria gonorrhoeae cause double-strand breaks and distort mitosis in epithelial cells during the human infection process. J. Med. Microbiol. 63, 1939–1949. https://doi.org/10.1099/jmm.0.07833-0.

World Health Organisation, 2018. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Int. Agency Res. Cancer. 2018. https://doi.org/10.1016/j.ijscr.2018.09.016.

Wu, S., Powers, S., Zhu, H., Hannum, Y.A., 2016. Substantial contribution of extrinsic risk factors to cancer development. Nature 539, 43–47. https://doi.org/10.1038/nature19165.

Xiong, M.H., Bai, Y., Xu, D.J., Bin, T., Zhang, J., Wang, X.H., Zhu, Y.H., Wang, J., 2013. Differential anticancer drug delivery with a nanogel sensitive to bacteria-associated accumulated tumor artificial environment. ACS Nano 7, 10366–10375. https://doi.org/10.1021/nn403146t.

Xiong, M.H., Zhang, W., Wang, J., Cao, Q., Zhou, L., Song, J., 2014. Photodynamic treatment enhancing the release of TRAIL from neutrophils through MMP-8. Int. J. Oncol. 42, 119–129. https://doi.org/10.3892/ijo.2013.2306.

Xu, Y., Yang, R., Cheng, L., Wang, M., Jiang, Y., Wang, S., 2011. LPS-induced outgrowth and metastasis by promoting lipid synthesis in lung cancer patients. Sci. Rep. 7, 1099. https://doi.org/10.1038/srep07349.

Xuan, C., Shamokii, J.M., Chung, A., DiNoelle, M.L., Chung, S., Sielinger, P.A., Lee, D.J., 2014. Microbial dysbiosis is associated with human breast cancer. PLoS ONE 9; 1. 9. https://doi.org/10.1371/journal.pone.0083744.

Y. Belkaid, T.H., 2015. Role of the microbiota in immunity and inflammatory Yasme. Cell 157, 121–141. https://doi.org/10.1016/j.cell.2014.03.011. Roland, Ramaguchi, F., Minakata, T., Miura, T., Suzuki, T., Sagara, H., 2020. Heterogeneity of latent tuberculosis infection in a patient with lung cancer. J. Infect. Public Health 13, 151–153. https://doi.org/10.1016/j.jiph.2019.09.009.

Yan, L., Kanada, M., Zhang, J., Okazaki, S., Terakawa, S., 2015. Photodynamic treatment of tumor with bacteria expressing killerred. PLoS ONE 10, 1. 10. https://doi.org/10.1371/journal.pone.0131518.

Yin, J., Zhang, W.W., Liu, L., Chen, M.C., Lee, C.H., 2018. Salmonella overcomes tumour drug resistance in tumour path through P-glycoprotein downregulation. Int. J. Med. Sci. 15, 574–579. https://doi.org/10.7150/ijms.22385.

Yang, J., Tan, Q., Fu, Z., Zhou, Y., Hu, Y., Tang, S., Zhou, Y., Zhang, J., Liu, X., 2017. Lactobacillus casei attenuated Listeria monocytogenes in a genetically engineered mouse model of latent tuberculosis infection in a patient with lung cancer. J. Infect. Public Health 13, 228–230. https://doi.org/10.1016/j.jiph.2017.07.009.

Yin, L., Xu, X., Han, Y., Jin, M., Ren, T., 2016. Gram-negative bacteria facilitate tumor outgrowth and metastasis by promoting lipid synthesis in lung cancer patients. J. Thorac. Dis. 8. 1943–1955. https://doi.org/10.7150/jtd.63317.

Yu, B., Yang, M., Shi, L., Yao, Y., Jiang, Q., Xi, Tang, L.H., Zheng, B.J., Yuen, K.Y., Smith, D.K., Song, E., Huang, J.D., 2012. Explicit hypoxia targeting with tumor suppression by creating an anisotropic Salmonella Typhimurium strain. Cell 148, 47–57. https://doi.org/10.1016/j.cell.2012.05.015.

Zhang, Y., Ying, C., Zhang, W., Liu, L., Chen, M.C., Lee, C.H., 2018. Salmonella overcomes tumour drug resistance in tumour path through P-glycoprotein downregulation. Int. J. Med. Sci. 15, 574–579. https://doi.org/10.7150/ijms.22385.

Zhao, L., Yang, R., Cheng, L., Wang, M., Jiang, Y., Wang, S., 2011. LPS-induced outgrowth and metastasis by promoting lipid synthesis in lung cancer patients. Sci. Rep. 7, 1099. https://doi.org/10.1038/srep07349.
Zhou, X., Chen, C., Zhong, Y.N., Zhao, F., Hao, Z., Xu, Y., Lai, R., Shen, G., Yin, X., 2020. Effect and mechanism of vitamin D on the development of colorectal cancer based on intestinal flora disorder. J. Gastroenterol. Hepatol. 35, 1023–1031. https://doi.org/10.1111/jgh.14949.

Zhuang, J., Sitti, M., 2016. Chemotaxis of bio-hybrid multiple bacteria-driven microswimmers. Sci. Rep. 6, 1–10. https://doi.org/10.1038/srep32135.

Zou, Y., Lei, W., Su, S., Bu, J., Zhu, S., Huang, Q., Li, Z., 2019. Chlamydia trachomatis plasmid-encoded protein Pgp3 inhibits apoptosis via the PI3K-AKT-mediated MDM2-p53 axis. Mol. Cell. Biochem. 452, 167–176. https://doi.org/10.1007/s11010-018-3422-9.